Amneal Delivers On Biosimilars Ambitions With Neupogen Rival

Company Also Reveals Plans For 20-30 Generics Launches In 2022

 
• By Akriti Seth
  
Growth
Amneal plans to grow on the back of new generics and biosimilar launches and pending approvals • Source: Alamy
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Products

More from Generics Bulletin